Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacillus coagulans unique IS2
- Development stage
- Unknown
- Lead developer
- Unique Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bacillus coagulans Unique IS2 is a spore-forming, lactic acid-producing probiotic strain developed by Unique Biotech. Characterized by its high stability and ability to survive gastric transit, the strain has been extensively studied for its therapeutic potential in gastrointestinal disorders. Clinical trials have demonstrated its efficacy in managing symptoms of irritable bowel syndrome (IBS) in both adults and children, as well as improving stool frequency and consistency in individuals with functional constipation. Beyond digestive health, Unique IS2 has shown promise in reducing caries-causing bacteria in oral health, managing examination-related stress in multi-strain formulations, and supporting weight management. In vitro research also indicates potential antiproliferative effects against colon cancer cells through the induction of apoptosis.
- Brand names
- Unique IS2
- Other names
- Bacillus coagulans Unique IS2B. coagulans Unique IS2
Beyond the preview
Go deeper on bacillus coagulans unique IS2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacillus coagulans unique IS2.